Mechanistically close to interchangeable: both are GLP-1 plus glucagon dual agonists without a GIP arm. The real difference is where each was developed and therefore who was studied.
Side by side
| Mazdutide | Survodutide | |
|---|---|---|
| Class | GLP-1 / glucagon dual agonist | GLP-1 / glucagon dual agonist |
| Status | Phase 3 investigational (China) | Phase 3 investigational |
| Route | Subcutaneous injection | Subcutaneous injection |
| Typical vials | 5 mg, 10 mg | 5 mg, 10 mg, 15 mg |
| Dose range | 2 mg to 6 mg | 0.6 mg to 4.8 mg |
| Frequency | Once weekly | Once weekly |
| Half-life | ~6.5 days | ~7 days |
| Dosing unit | milligrams | milligrams |
Pharmacokinetics
What the evidence supports
These grade how well each outcome has been studied in humans, never how well either compound works. A strong grade can sit on a negative result.
Both top out at the same tier of evidence: Human RCT. Where they differ is in which outcomes have been asked about, not in how well either has been studied overall.
Mazdutide
| Outcome | Evidence |
|---|---|
| Glycemic control | Human RCT |
| Weight loss | Human RCT |
| Cardiovascular outcomes | No data |
Survodutide
| Outcome | Evidence |
|---|---|
| MASH / liver fibrosis | Human RCT |
| Weight loss | Human RCT |
| Long-term safety | No data |
How to choose
Mazdutide's evidence is largely from Chinese populations
Which matters for dosing, because the effective doses studied there run lower than the Western incretin programs.
Survodutide has the MASH biopsy data
Mazdutide's liver evidence is thinner.
Neither has a completed global Phase 3 with outcome endpoints
Both are still weight and surrogate-marker programs.
At the syringe
At the default setup on each compound's own page, a 10 mg vial in 2 mL puts 50 mcg on every insulin unit, while a 10 mg vial in 2 mL puts 50 mcg on every unit. That is the number that decides whether a dose lands on a readable mark, and it is set by how much water goes in, not by the compound.